...
首页> 外文期刊>European radiology >Percutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysms: short- and midterm ultrasound follow-up.
【24h】

Percutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysms: short- and midterm ultrasound follow-up.

机译:人凝血酶的经皮注射治疗医源性股假性动脉瘤:短期和中期超声随访。

获取原文
获取原文并翻译 | 示例

摘要

Our objective was to determine the efficacy of ultrasound-guided direct injection of human thrombin to close postcatheterization pseudoaneurysms and to evaluate the midterm results of this new percutaneous technique by ultrasound follow-up. One hundred one postcatheterization pseudoaneurysms in 100 patients were treated by direct injection of human thrombin (mean dose 200 IU, range 50-750 IU) under ultrasound guidance. Patient demographics, clinical data and ultrasonographic morphology of the pseudoaneurysms were analyzed. Midterm (mean 99 days, range 25-210 days) ultrasonographic follow-up was performed in 57 of 82 called patients (69.5%). Ninety-six of 101 pseudoaneurysms thrombosed completely after the first procedure. Of the remaining 5 pseudoaneurysms, 3 were treated successfully after the second attempt, and 2 patients underwent surgical repair; thus, the primary success rate was 95% (96 of 101), and the overall success rate was 98% (99 of 101). No changes in distal pulses or other adverse eventswere noted immediately or 1 day after the procedure. Ultrasound follow-up revealed complete disappearance of the pseudoaneurysm in 70% (40 of 57), presence of small, residual groin hematoma in 26% (15 of 57), and partial reperfusion of the pseudoaneurysm in 3.5% (2 of 57). Human thrombin injection under ultrasound guidance is a very effective and safe method of therapy. Failure (immediate and late) of the technique as well as procedure-related complications are very rare. In our institution, sonographically guided human thrombin injection has become the treatment of choice for postcatheterization pseudoaneurysms.
机译:我们的目标是确定超声引导下的人凝血酶直接注射对闭合导管后假性动脉瘤的疗效,并通过超声随访评估这种新的经皮技术的中期结果。在超声引导下,通过直接注射人凝血酶(平均剂量200 IU,范围50-750 IU)治疗100例患者中的101个导管插入后假性动脉瘤。分析了患者的人口统计学,临床资料和假性动脉瘤的超声形态学。在82名被叫患者中,有57名(69.5%)接受了中期(平均99天,范围为25-210天)超声检查。第一次手术后,101例假性动脉瘤中有96例完全血栓形成。在其余的5个假性动脉瘤中,有3个在第二次尝试后成功治疗,2例接受了手术修复。因此,一次成功率为95%(101个中的96个),总体成功率为98%(101个中的99个)。手术后立即或手术后1天未观察到远端脉搏或其他不良事件的变化。超声随访显示假性动脉瘤完全消失的比例为70%(57个中的40个),残留的小腹股沟血肿为26%(57个中的15个),假性动脉瘤的部分再灌注为3.5%(57个中的2个)。在超声引导下注射人凝血酶是一种非常有效和安全的治疗方法。该技术的失败(中,晚期)以及与手术相关的并发症非常少见。在我们的机构中​​,超声引导下的人类凝血酶注射已成为导管插入后假性动脉瘤的首选治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号